[New therapeutic approaches for solid tumors: histone deacetylase, methyltransferase and proteasome inhibitors].
Recent results from basic and translational research on tumor genesis and progression establish the basis for future therapeutic approaches. Targeted therapeutics are tailored toward the molecular abnormalities that cause tumor progression and could potentially provide an effective, non-toxic therapeutic approach in a broad range of cancers including melanoma. Cancer is as much a (cyto)genetic disease as it is an epigenetic disease. Indeed, the fate of the cell depends on a delicate balance between expression and repression of genes. The notion that drastic changes in DNA methylation and histone modifications are present in a variety of human tumors has prompted the development and characterization of epigenetic drugs. Inhibitors of histone deacetylases and methyltransferases as well as of the proteasome are covered in this review.
Becker
Jürgen C
JC
Universitätsklinik Würzburg, Josef-Schneider-Str. 2, D-97080 Würzburg. becker_jc@klinik.uni-wuerzburg.de
Ugurel
Selma
S
Bröcker
Eva-Bettina
EB
Schrama
David
D
Houben
Roland
R
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002471:Cell Transformation, Neoplastic / Q000187:drug effects; D015254:DNA Modification Methylases; D056572:Histone Deacetylase Inhibitors; D006801:Humans; D008545:Melanoma / Q000188:drug therapy / Q000235:genetics; D008780:Methyltransferases / Q000037:antagonists & inhibitors*; D061988:Proteasome Inhibitors; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000235:genetics
D000970:Antineoplastic Agents; D056572:Histone Deacetylase Inhibitors; D061988:Proteasome Inhibitors; D015254:DNA Modification Methylases; D008780:Methyltransferases